TrialInvestigational new drugs2023

A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.

Elizabeth I Buchbinder et al.PubMed ↗Publisher ↗

No numbers read from the abstract.